Traws Pharma, Inc.
TRAW
$0.54
-$0.01-2.26%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | 4,694.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | 4,694.74% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -- | 4,694.74% |
| SG&A Expenses | 105.74% | -26.14% | -32.88% | -49.89% | -14.47% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.27% | 32.05% | 38.13% | -52.81% | -32.97% |
| Operating Income | -154.20% | -33.50% | -39.60% | 52.50% | 78.77% |
| Income Before Tax | -233.77% | -133.07% | 75.13% | 53.25% | 99.26% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -233.77% | -133.07% | 75.13% | 53.25% | 99.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -233.77% | -133.07% | 75.13% | 53.25% | 99.26% |
| EBIT | -154.20% | -33.50% | -39.60% | 52.50% | 78.77% |
| EBITDA | -150.88% | -32.68% | -38.82% | 52.66% | 78.78% |
| EPS Basic | -53.26% | -124.70% | 91.71% | 76.91% | 99.20% |
| Normalized Basic EPS | -22.51% | -121.65% | 91.81% | 94.90% | 96.33% |
| EPS Diluted | -49.64% | -125.59% | 91.71% | 76.91% | 99.18% |
| Normalized Diluted EPS | -22.51% | -122.42% | 91.81% | 94.90% | 96.33% |
| Average Basic Shares Outstanding | 172.54% | 52.75% | 203.89% | 817.20% | 338.29% |
| Average Diluted Shares Outstanding | 172.54% | 47.48% | 203.89% | 817.20% | 338.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |